Overview

Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

Status:
Recruiting

Trial end date:
2034-12-31

Target enrollment:

Participant gender:

Summary

This research study is being offered to those patients who have received radiation therapy and who are receiving long-term hormonal therapy for their prostate cancer and whose PSA remains detectable despite having received at least 6, but no more than 12 months of hormonal therapy. The name of the study drugs involved in this study is: - LHRHA (luteinizing hormone-releasing hormone agonist or antagonist) - Abiraterone Acetate - Apalutamide - Prednisone

Phase:

Phase 3

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborator:

Janssen Scientific Affairs, LLC

Treatments:

Abiraterone Acetate
Androgens
Prednisone